Patrick B. Deegan
University of Cambridge · 176 works · 6,225 citations · h-index 39
Top works
- Natural history of Fabry disease in females in the Fabry Outcome Survey
- Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease
- A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency
- Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
- Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study
- Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease
- Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease
- Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis
- Phenotypic Characterization of EIF2AK4 Mutation Carriers in a Large Cohort of Patients Diagnosed Clinically With Pulmonary Arterial Hypertension
- Whole-genome sequencing of a sporadic primary immunodeficiency cohort
- Clinical Effect And Safety Profile of Recombinant Human Lysosomal Acid Lipase in Patients With Cholesteryl Ester Storage Disease
- Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
- Osseous Manifestations of Adult Gaucher Disease in the Era of Enzyme Replacement Therapy
- Gaucher Disease in Bone: From Pathophysiology to Practice
- Clinical Features of Lysosomal Acid Lipase Deficiency
- Monitoring enzyme replacement therapy in Fabry disease—Role of urine globotriaosylceramide
- Sebelipase alfa over 52weeks reduces serum transaminases, liver volume and improves serum lipids in patients with lysosomal acid lipase deficiency
- Prognostic value of troponin T in hemodialysis patients is independent of comorbidity
- The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease
- Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis